
				ATTY DOCKET NO. 022438.43867	APPLICATION NO. 09/965.738	
APPLICANT(S) O'Brien, et al.						
FILING DATE September 27, 2001				GROUP ART UNIT 1642		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
U.S. PATENT APPLICATION PUBLICATIONS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
GW	AA WO 00/36107	06/22/00	World	C12N 15/12	C07K 14/47	<input checked="" type="checkbox"/>
GW	BB 0 288 082	10/26/88	Europe	C07K 15/14	C12P 21/00	<input checked="" type="checkbox"/>
GW	CC WO 02/092836	11/21/02	World	C12Q		<input checked="" type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
GW	DD	More than 15 years of CA125: What is known about the antigen, its structure and its function T.J. O'Brien, et al. The International Journal of Biological Markers, Vol. 13, no. 4, pp. 188-195				
GW	EE	Isolation and Characterization of Ovarian Cancer Antigen CA125 Using a New Monoclonal Antibody (VK-8): Identification as a Mucin-type Molecule Kenneth O. Lloyd, et al. Int. J. Cancer: 71, 842-850 (1997)				
EXAMINER <i>Gangarajkumar</i>			DATE CONSIDERED 2/7/06			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

<p style="text-align: center;">O P F INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i></p> <p style="text-align: center;">DEC 02 2006</p>		Docket Number (Optional) 022438.43867	Application Number 09/965,738
		Applicant(s) O'Brien, et al.	
		Filing Date September 27, 2001	Group Art Unit 1642
<p>EXAMINER <i>GW</i> OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i></p>			
	FF	<p>"Immunohistochemical Characterization of 22 Monoclonal Antibodies against the CA125 Antigen 2nd Report from the ISOBO M TD-1 Workshop" M. Nap, et al. Tumor Biol. 1996; 17: 325-331</p>	
	GG	<p>"Human Mucin Gene MUC5B, the 10.7-kb Large Central Exon Encodes Various Alternate Subdomains Resulting in a Super-repeat" Jean-Luc Desseyen, et al. The Journal of Biological Chemistry, Vol. 272, No. 6, Issue of February 7, pp. 3168-3178 (1997)</p>	
	HH	<p>"Isolation of the Murine Nbr1 Gene Adjacent to the Murine Brcal Gene" Julie Chambers, et al. Genomics 38, 305-313 (1996)</p>	
	II	<p>http://www.ncbi.nlm.nih.gov/entrez/viewer.cgi?db=nucleotide&val=2566012 "Nucleotide" Lee Helman, M.D., et al. NCBI Sequence Viewer</p>	
	JJ	<p>"Molecular Cloning of the CA125 Ovarian Cancer Antigen" Beatrice W.T. Yin, et al. The Journal of Biological Chemistry, Vol. 276, No. 29, Issue of July 20, pp. 27371-27375 (2001)</p>	
	KK	<p>"The CA125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences" Timothy J. O'Brien, et al. Tumor Biol. 2001; 22: 348-366</p>	
	LL	<p>"The CA125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure" Timothy J. O'Brien, et al. Tumor Biol 2002; 23: 154-169</p>	
<p>EXAMINER <i>Gary B Michael</i></p>		<p>DATE CONSIDERED <i>2/7/06</i></p>	
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			



EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p style="text-align: center;">O I P E INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i></p> <p style="text-align: center;">FEB 02 2004</p> <p style="text-align: center;">EXAMINER <i>Gary B. Mihal</i></p>		Docket Number (Optional) 022438.43867	Application Number 09/965,738
		Applicant(s) O'Brien, et al.	
		Filing Date September 27, 2001	Group Art Unit 1642
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
AA	<p>O'Brien, et al. "The CA125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences" Tumor Biology, Vol. 22, 2001 pp. 348-366 <i>Duplicate</i></p>		
BB	<p>Argueso, et al. "MUC16 Mucin is Expressed by the Human Ocular Surface Epithelia and Carries the H185 Carbohydrate Epitope" Invest Ophthalmol Vis Sci 2003 Jun;44(6):2487-95</p>		
<p>EXAMINER <i>Gary B. Mihal</i> DATE CONSIDERED <i>2/7/06</i></p> <p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

<p style="text-align: center;">INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small></p> <p style="text-align: center;">MAY 10 2005 U.S. PATENT & TRADEMARK OFFICE</p>				Docket Number (Optional) 022438.43865		Application Number 09/965,738		
				Applicant(s) Timothy J. O'Brien				
				Filing Date 9/27/01		Group Art Unit 1642		
				U.S. PATENT DOCUMENTS				
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>GW</i>	AA	6,335,194	1-1-2002	Bennett et al.	435/375		2-2-2000	
<i>GW</i>	BB	6,451,602	9-17-2002	Popoff et al.	435/375		3-2-2000	
U.S. PATENT APPLICATION PUBLICATIONS								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	
							NO	
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
EXAMINER	<i>Jany B. Mikal</i>		DATE CONSIDERED <i>2-7-06</i>					
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many photos as necessary)

Sheet 1 of 7

Complete if Known

Application Number	09/965,738
Filing Date	September 27, 2001
First Named Inventor	O'Brien, Timothy J.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	40715-260477
Express Mail Certificate	EV 032 104 775 US

Express Mail Certificate EV 032 104 775 US

MAR 11 2002

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449APTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/965,738
Filing Date	September 27, 2001
First Named Inventor	O'Brien, Timothy J.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	40715-260477

O P E

MAR 11 2002

U.S. PATENT & TRADEMARK OFFICE

Sheet

2

of

3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GW	1	BAST RC et al., A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, <i>N Engl J Med.</i> 309:883-887 (1983)	✓
GW	2	BON GC et al., Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values, <i>Am J Obstet. Gynecol.</i> 174:107-114 (1996)	✓
GW	3	CLEMONS-MILLER, A et al. Intrathecal Cytotoxic T-Cell Immunotherapy for Metastatic Leptomeningeal Melanoma. <i>Clinical Cancer Research</i> 7:917s-924s, March 2001 (Suppl.)	✓
Duplicate	4	DESSEYN JL et al., Human mucin gene MUC5B, the 10.7-kb large central exon encodes various alternate subdomains resulting in a super-repeat. Structural evidence for a 11p15.5 gene family, <i>J Biol. Chem.</i> 272(6):3168-3178 (1997)	✓
GW	5	FENDRICK, JL et al. Characterization of CA 125 Synthesized by the Human Epithelial Amnion WISH Cell Line. <i>Tumor Biol.</i> 1993; 14:310-318	✓
	6	FENDRICK, JL et al. CA125 Phosphorylation Is Associated with Its Secretion from the WISH Human Amnion Cell Line. <i>Tumor Biol.</i> 1997; 18:278-289	✓
	7	FOON, KA et al., Are solid tumor anti-idiotypic vaccines ready for prime time?, <i>Clinical Cancer Research</i> 7:1112-1115 (2001)	✓
	8	GENDLER SJ et al., Epithelial mucin genes, <i>Annu. Rev. Physiol.</i> 57:607-634 (1995)	✓
	9	GUM Jr., JR, Mucin genes and the proteins they encode: Structure, diversity and regulation, <i>Am J Respir. Cell Mol. Biol.</i> 7:557-564 (1992)	✓
	10	GUM JR, Human Mucin Glycoproteins: Varied Structures Predict Diverse Properties and Specific Functions. <i>Biochemical Society Transactions.</i> 23(4):795-799, 1995.	✓
	11	HARDARDOTTIR H et al., Distribution of CA125 in embryonic tissue and adult derivatives of the fetal periderm, <i>Am J Obstet. Gynecol.</i> 163;6(1):1925-1931 (1990)	✓
	12	KONISHI I et al., Epidermal growth factor enhances secretion of the ovarian tumor-associated cancer antigen CA125 from the human amnion WISH cell line, <i>J Soc. Gynecol. Invest.</i> 1:89-96 (1994)	✓
	13	LLOYD KO et al., Synthesis and secretion of the ovarian cancer antigen CA125 by the human cancer cell line NIH: OVCAR-3, <i>Tumor Biology</i> 22, 77-82 (2001)	
	14	LLOYD KO et al., Isolation and characterization of ovarian cancer antigen CA125 using a new monoclonal antibody (VK-8). Identification as a uchin-type molecule, <i>Int. J. Cancer</i> , 71:842-850 (1997) — Duplicate	✓
GW	15	MARSHALL E, DNA Sequencing: Genome teams adjust to shotgun marriage, <i>Science</i> 292:1982-1983 (2001)	✓
	16	NAP M et al., Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2 nd report from the ISOBM TD-1 workshop, <i>Tumor Biology</i> 17:325-331 (1996) — Duplicate	✓
GW	17	NUSTAD K et al., CA125 - epitopes and molecular size, <i>Int. J. of Biolog. Markers.</i> 13(4):196-199 (1998)	✓

Substitute for form 1449APTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/965,738
Filing Date	September 27, 2001
First Named Inventor	O'Brien, Timothy J.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	40715-260477

CW	18	NUSTAD K et al., Specificity and affinity of 26 monoclonal antibodies against the CA125 antigen: First report from the ISOBM TD-1 workshop <i>Tumor Biology</i> 17:196-219 (1996)	✓
	19	O'BRIEN, TJ et al. CA 125 Antigen in Human Amniotic Fluid and Fetal Membranes. <i>Am J Obstet Gynecol</i> 155:50-55 July, 1986	
	20	O'BRIEN, TJ et al. New Monoclonal Antibodies Identify the Glycoprotein Carrying the CA 125 Epitope. <i>Am J Obstet Gynecol</i> 1991; 165:1857-64	✓
	21	O'BRIEN, TJ et al. More Than 15 Years of CA 125: What Is Known about the Antigen, Its Structure and Its Function. <i>The International Journal of Biological Markers</i> 13:188-195 (1998) — Duplicate —	
CW	22	QUIRK, JR et al. CA 125 in Tissues and Amniotic Fluid During Pregnancy. <i>Am J Obstet Gynecol</i> 159:655-649 (1988)	✓
	23	SANTIN, AD et al. Induction of Ovarian Tumor-Specific CD8+ Cytotoxic T Lymphocytes by Acid-Eluted Peptide-Pulsed Autologous Dendritic Cells. <i>Obstetrics & Gynecology</i> 2000; 96:422-30	
	24	SANTIN, AD et al. In vitro Induction of Tumor-Specific Human Lymphocyte Antigen Class I-Restricted CD8+ Cytotoxic T Lymphocytes by Ovarian Tumor Antigen-Pulsed Autologous Dendritic Cells from Patients with Advanced Ovarian Cancer. <i>Am J Obstet Gynecol</i> 2000; 183:601-9	✓
	25	SHIGESMASA, K, et al. p21: a Monitor of p53 Dysfunction in Ovarian Neoplasia. <i>International Journal of Gynecologic Cancer</i> 7:296-303, 1997.	✓
	26	SHIGESMASA, K, et al. p16 Overexpression: A Potential Early Indicator of Transformation in Ovarian Carcinoma. <i>J Soc Gynecol Invest</i> 4:95-102, 1997.	✓
	27	VERMA M et al., Mucin genes: Structure, expression and regulation, <i>Glycoconjugate J.</i> 11:172-179 (1994)	✓
	27	WAGNER, U. et al. Immunological Responses to the Tumor-Associated Antigen CA125 in Patients with Advanced Ovarian Cancer Induced by the Murine Monoclonal Anti-Idiotype Vaccine ACA125. <i>HYBRIDOMA</i> 16:33-40 (1997)	✓
	29	WAGNER U et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: Immune responses and survival in palliative treatment, <i>Clin. Cancer Res.</i> 7:1112-1115 (2001)	✓
	30	WILLIAMS, SJ et al. MUC13, a Novel Human Cell Surface Mucin Expressed by Epithelial and Hemopoietic Cells. <i>The Journal of Biological Chemistry</i> 276(21):18327-18336, 2001.	✓
	31	YIN TWT et al., Molecular cloning of the CA125 ovarian cancer antigen. Identification as a new mucin (MUC16), <i>J Biol. Chem.</i> 276:27371-27375 (2001)	✓
	32	ZURAWSKI VR et al., Tissue distribution and characteristics of the CA125 antigen, <i>Cancer Rev.</i> 11-12:102-118 (1998)	✓

Examiner
Signature

Mangano, Richard

Date
Considered

2/7/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 911366